Lisa Leypoldt
-
- Multiple Myeloma Research and Treatments 11
-
- Peptidase Inhibition and Analysis 3
- CAR-T cell therapy research 2
-
- T-cell and B-cell Immunology 2
-
- SARS-CoV-2 and COVID-19 Research 2
-
- Protein Degradation and Inhibitors 7
-
- Cancer Mechanisms and Therapy 2
-
- Chronic Lymphocytic Leukemia Research 2
- Co-authors
- Katja WeiselCarsten BokemeyerJulian Schulze zur WieschWalter FiedlerMarianne SinnMartin SchönleinGabi VohwinkelHeiko Becher
- Cited by
- HematologyOncologyImmunology
- Partner nations
- GermanyGreeceUnited States
In The Last Decade
Lisa Leypoldt
10 papers receiving 92 citations
Peers
Comparison fields: 5 of 23
- Hematology 33
- Oncology 50
- Immunology 36
- Infectious Diseases 26
- Health 4
Countries citing papers authored by Lisa Leypoldt
This map shows the geographic impact of Lisa Leypoldt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lisa Leypoldt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lisa Leypoldt more than expected).
Fields of papers citing papers by Lisa Leypoldt
This network shows the impact of papers produced by Lisa Leypoldt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lisa Leypoldt. The network helps show where Lisa Leypoldt may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Lisa Leypoldt, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 0 | |
| 4 | 2024 | 0 | |
| 5 | 2024 | 12 | |
| 6 | 2023 | 2 | |
| 7 | 2023 | 1 | |
| 8 | 2022 | 2 | |
| 9 | 2022 | 1 | |
| 10 | 2021 | 24 | |
| 11 | 2021 | 13 | |
| 12 | 2021 | 5 | |
| 13 | 2021 | 30 | |
| 14 | 2021 | 2 |
About Lisa Leypoldt
Lisa Leypoldt is a scholar working on Hematology, Oncology and Immunology, having authored 14 papers that have together received 92 indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (11 papers), Protein Degradation and Inhibitors (7 papers), Peptidase Inhibition and Analysis (3 papers), SARS-CoV-2 and COVID-19 Research (2 papers), Cancer Mechanisms and Therapy (2 papers), Chronic Lymphocytic Leukemia Research (2 papers), CAR-T cell therapy research (2 papers) and T-cell and B-cell Immunology (2 papers). The work is most often cited by research in Hematology (33 citations), Oncology (50 citations) and Immunology (36 citations). Lisa Leypoldt has collaborated with scholars based in Germany, Greece and United States. Frequent co-authors include Katja Weisel, Carsten Bokemeyer, Julian Schulze zur Wiesch, Walter Fiedler, Marianne Sinn, Martin Schönlein, Gabi Vohwinkel, Heiko Becher, Marc Lütgehetmann and Franziska Brauneck. Their work appears in journals such as Journal of Clinical Oncology, Blood and Cancers.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.